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Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of  coronavirus dis-
ease 2019 (COVID-19) (1). SARS-CoV-2 infections were initially reported in China near the beginning of  
December 2019 (2). After early spread through Asia, and subsequently to European, American, and African 
countries, the virus is responsible for the third pandemic of  the 21st century. With currently (late July, 2020) 
over 48 million confirmed cases and greater than 1.2 million deaths worldwide, health systems are stretched 
beyond their limits with largely no proven treatment or prophylaxis available to reduce the burden (3). Public 
health measures combined with increasingly severe restrictions on public life have been implemented in many 
countries to stop SARS-CoV-2 transmission. The goal of  public health strategies is still to flatten the epide-
miologic SARS-CoV-2/COVID-19 curve to ease the burden on health care systems challenged by the highly 
intensive care required for a significant proportion of  COVID-19 cases. Over 1000 clinical trials are currently 
open or being established in different countries testing drugs such as lopinavir/ritonavir, dexamethasone, 
hydroxychloroquine (HCQ), and inhaled IFN-β–1a (4). Yet, many of  these treatments have not been empir-
ically tested in relevant SARS-CoV-2 animal disease models to determine preclinical efficacy, which would 
possibly provide valuable insight into prioritization of  drugs to move forward in humans.
At the time this work was started, the FDA had given emergency approval for the use of  chloroquine 
and HCQ in patients with COVID-19 (5). In vitro data on the inhibitory effect of  chloroquine and HCQ on 
SARS-CoV-2 replication had been published (6–8) and HCQ alone or in combination with the macrolide 
antibiotic azithromycin had been used in early clinical trials to treat COVID-19 cases with varying effect 
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although 
many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive 
preclinical drug efficacy studies to help guide decisions. Here we assessed the prophylactic/
therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in 
2 animal disease models. The standard human malaria HCQ prophylaxis (6.5 mg/kg given weekly) 
and treatment (6.5 mg/kg given daily) did not significantly benefit clinical outcome, nor did it 
reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus 
macaque disease model. Similarly, when used for prophylaxis or treatment, neither the standard 
human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on 
clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. 
Results from these 2 preclinical animal models may prove helpful in guiding clinical use of HCQ for 
prophylaxis/treatment of COVID-19.
2insight.jci.org   https://doi.org/10.1172/jci.insight.143174
R E S E A R C H  A R T I C L E
(9–11). Despite ongoing clinical trials, preclinical efficacy data on the effect of  HCQ in SARS-CoV-2 ani-
mal disease models were lacking. Herein, we assessed the efficacy of  HCQ prophylaxis and treatment in 2 
established animal disease models, the Syrian hamster and rhesus macaque (12, 13).
Results
First, we confirmed the in vitro inhibitory effect of  HCQ on SARS-CoV-2 replication in Vero E6 cells. 
Cells were pretreated with differing drug concentrations and the effect on viral RNA load in tissue culture 
supernatant was determined 72 hours after infection by quantitative reverse transcriptase PCR (qRT-PCR) 
(Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.143174DS1). The half-maximal effective concentration (EC50) value for HCQ in our studies was 
164.7 nM. Published EC50 values for inhibitors of  SARS-CoV-2 have been shown to vary considerably 
(~2-logs) even within the same cell type (14), which is presumably due to differences in methods of  anal-
yses used in the different studies. Although the value of  164.7 nM is lower than seen in other studies, it is 
consistent with low/submicromolar levels (0.7 to 17 uM) previously reported for the established in vitro 
inhibitory effect of  HCQ on SARS-CoV-2 replication in Vero E6 cells (7, 8, 14).
Having confirmed in vitro efficacy, next, we assessed HCQ efficacy in the rhesus macaque, the only 
animal model at that time displaying mild-to-moderate COVID-like disease upon SARS-CoV-2 infection 
(13). We investigated the effect of  HCQ when administered either prophylactically or as a treatment after 
infection. A wide variety of  different HCQ-dosing protocols are used in both preexposure and postexposure 
prophylaxis studies as well as for treatment of  patients with COVID-19 (4, 15, 16). Our HCQ prophylaxis 
study design was based on the approved Plaquenil regimen, which comprises a single weekly dose (6.5 
mg/kg) to ensure adequate tissue loading (17, 18). Similarly, for therapeutic treatment, the recommended 
treatment for malaria of  6.5 mg/kg was followed, except that the initial 13 mg/kg loading dose was divided 
over 2 boluses 6 hours apart (17, 18). This treatment regimen has demonstrated established efficacy against 
malaria infection with minimal toxicity.
For the prophylactic arm, 10 healthy rhesus macaques were randomly divided into vehicle control and 
HCQ prophylaxis groups (n = 5 per group). Animals were treated by oral gavage with either vehicle (PBS) or 
HCQ (6.5 mg/kg in PBS) 3 times 1 week apart (day –9, day –2, and day 5) (Figure 1A). To test the efficacy 
of  HCQ as a treatment, a separate group of  10 healthy rhesus macaques were randomly divided into vehicle 
control and HCQ treatment groups (n = 5 per group). Animals were treated by oral gavage with either vehicle 
(PBS) or HCQ (6.5 mg/kg in PBS) starting 12 hours after infection followed by treatment 18, 36, 60, 84, 108, 
132, and 156 hours after infection (Figure 1B). Animals in all groups were infected on day 0 with a total dose 
of  2.8 × 106 median tissue culture infectious doses (TCID50) of  SARS-CoV-2 by a combination of  4 routes 
(intratracheal, oral, intranasal, and ocular) as previously established (13). Animals were monitored at least 
twice daily using an established scoring sheet designed to assess clinical signs of  disease (13, 19). Multiple 
physical examinations were performed on different days preinoculation and after inoculation including a 
clinical evaluation, radiographs, blood collection, and swabs (oral and nasal). Bronchoalveolar lavage (BAL) 
was performed on days 3, 5, and 7 (postmortem) (Figure 1, A and B). The endpoint for both studies was day 7 
after infection, at which time all animals were euthanized and necropsied. This time point represents the best 
compromise between assessment of  clinical progression and viral replication kinetics in tissues.
To assess the pharmacokinetics of  HCQ in the animals, HCQ and its secondary metabolites were 
measured immediately before redosing, thus reflecting the minimum plasma concentration over the experi-
ment. HCQ was detected in plasma samples in all prophylactically or therapeutically treated animals, with 
concentration ranging from 2 to 31 nM and 24 to 292 nM, respectively (Figure 1, C and D). HCQ was 
also detected in lung tissue at time of  necropsy in all prophylactically or therapeutically treated animals, 
ranging from 1.5 to 12.5 nmol/g tissue and 4.1 to 34.3 nmol/g tissue, respectively. These numbers are in 
good agreement with the reported long half-life and large volume of  distribution of  HCQ (20–24). HCQ 
cytochrome p450 catalyzed secondary amine metabolites desethylchloroquine and desethylhydroxychlo-
roquine and the primary amine metabolite bisdesethylchloroquine are considered to be active forms of  
the drug in other disease models (25). Both desethylchloroquine and desethylhydroxychloroquine were 
detected in intermediate concentrations, whereas trace amounts of  bisdesethylchloroquine was detected in 
lung homogenate, suggesting persistence of  active drug forms over the course of  treatment (Supplemental 
Figure 2). The minimum plasma HCQ levels measured here are comparable with plasma levels found in 
human prophylactic and therapeutic ranges for malaria prevention and are consistent with the expected 
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low plasma levels 12 to 24 hours after administration (26, 27). Based on these previously published studies, 
the initial maximum concentration of  HCQ is expected to be 2 to 3 orders of  magnitude higher than these 
minimum values with a rapid clearance from the bloodstream into the tissue (21). Because SARS-CoV-2 is 
a respiratory disease, levels of  drug in lung tissue are presumably the best indicator of  therapeutic poten-
tial. Volume/concentration can be difficult to estimate in tissues due to compartmentalization of  the drug, 
resulting in a nonhomogenous distribution. On average, water content of  the lung is approximately 80% by 
weight and this number can be used to calculate an estimated HCQ concentration in the tissue, assuming a 
homogenous distribution (28). Using these values, levels in the lung on day 7 were approximately 3.0 μM at 
a minimum. As indicated, published EC50 values vary considerably; however, this value of  approximately 
3.0 μM falls within the range of  previously published (7, 8, 14) in vitro EC50 values for HCQ (0.7 to 17 μM).
Macaques in both the prophylactic and treatment arms of  the study first displayed clinical signs of  
SARS-CoV-2 infection on day 1, which peaked on day 2 and animals remained mildly to moderately ill 
Figure 1. Rhesus macaque model — design, drug concentrations, and clinical scoring. Macaques were infected with SARS-CoV-2 by the combined intra-
tracheal, intranasal, oral, and ocular routes. Animals were treated by oral gavage with either vehicle (PBS) or HCQ (6.5 mg/kg in PBS). Administration was 
either 1 time per week for the prophylaxis arm or starting 12 hours after infection followed by treatment 18, 36, 60, 84, 108, 132, and 156 hours after infec-
tion for the treatment arm. Animals were scored for clinical disease twice daily and examinations were performed as indicated. (A and B) Study design. 
The schematic depicts SARS-CoV-2 infection (I), HCQ or vehicle treatment (T), examinations (E), and necropsy (N). (C and D) Plasma levels of HCQ. HCQ 
levels were determined in both the prophylaxis and treatment study arms. Measurements reflect predose levels of HCQ at each time point (limit of quan-
tification = 1.5 nM). (E and F) Clinical scores. Clinical scoring was performed twice daily by observation of nonanesthetized animals. The morning score is 
graphed here. Red squares indicate vehicle-treated animals and blue circles indicate HCQ-treated animals. SARS-CoV-2, severe acute respiratory syndrome 
coronavirus 2; HCQ, hydroxychloroquine; PS, prophylaxis; TS, treatment.
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until the study endpoint on day 7 (Figure 1, E and F). Clinical signs included reduced appetite and ruf-
fled fur followed by pale appearance and irregular increased abdominal respiration (Supplemental Table 
1). Macaques did not develop fevers or coughs after SARS-CoV-2 infection and weight loss was minimal 
between groups. Overall, animals in the vehicle-treated groups appeared to have slightly higher clinical 
scores throughout; however, multiple t tests performed on individual days found no significant differences 
between groups. Hematology and serum chemistry were unremarkable for all animals in both study arms. 
Radiographic signs in the prophylaxis, treatment, and control groups were minimal over the study course 
(Supplemental Figure 3). Pulmonary infiltrates, when seen, were noted to be of  a mild unstructured inter-
stitial pattern. The pattern was rarely seen in the upper lung, being more commonly found in middle and 
caudal lung lobes. No differences were noted in severity or appearance of  radiographic signs between HCQ 
prophylaxis, treatment, or control groups.
Nasal and oropharyngeal swabs were positive for SARS-CoV-2 RNA in all animals of  both studies, 
with the highest load on either day 1 or day 3, which then gradually decreased until the end of  the study 
(Figure 2, A–D). Viral loads were consistently higher in nasal swabs than oropharyngeal swabs. BAL sam-
ples were collected on days 3, 5, and 7 (postmortem) and viral loads were similar to nasal and oropharyn-
geal swabs, with decreasing loads over time (Figure 2, E and F). Overall, there were no statistically signifi-
cant differences in virus load and shedding between HCQ-administered and vehicle-administered animals 
in the prophylaxis and treatment regimens.
At necropsy, gross pathology revealed consolidated lungs in animals of  all groups, with lesions observed 
largely in the lower lung lobes, although some of  the lesions may have been the result of  the postmortem 
BAL (Figure 3, A and B). All other gross pathology was normal except for enlarged cervical and mediastinal 
lymph nodes in several animals across the groups. Histological analysis of  the lungs of  animals in the different 
prophylaxis and treatment groups determined a comparable degree of  pulmonary pathology when inoculated 
with SARS-CoV-2, similar to what had been previously published (13) (Figure 3C). Lesions were mild to 
moderate and characterized as multifocal interstitial pneumonia frequently centered on terminal bronchioles. 
The pneumonia was evident by a thickening of  alveolar septae by edema fluid and fibrin and small-to-mod-
erate numbers of  macrophages and fewer neutrophils. Infiltration of  small numbers of  pulmonary macro-
phages and neutrophils were noticed in alveoli. Lungs with moderate changes also had alveolar edema and 
fibrin with formation of  hyaline membranes. There was minimal-to-moderate type II pneumocyte hyper-
plasia. Occasionally, bronchioles had necrosis and loss and attenuation of  the epithelium with infiltrates of  
neutrophils, macrophages, and eosinophils. Perivascular infiltrates of  small numbers of  lymphocytes forming 
perivascular cuffs were noticed multifocally (Figure 3C). Overall, there was no apparent difference between 
vehicle-treated and HCQ-treated animals in either of  the regimens, prophylaxis or treatment.
Viral RNA loads were determined in several respiratory tissues using qRT-PCR (Figure 4, A and C). 
Highest genome copy numbers were found in distal lung tissue, with a marginal but not statistically sig-
nificant benefit for the HCQ-treated over the vehicle-treated group in the prophylaxis study arm when all 
lung lobe samples were combined (Figure 4, B and D). Virus isolation from tissues was inconsistent among 
animals in the different groups, but at least 1 sample in each group showed infectious virus for almost all 
respiratory tissues (Figure 4, A and C). There was no significant difference between vehicle-treated and 
HCQ-treated groups in the prophylaxis and treatment study arms, which is consistent with the lack of  any 
observed benefit of  HCQ on virus shedding parameters.
HCQ has been suggested to have immunomodulatory effects. We therefore also evaluated the lung 
concentrations of  proinflammatory cytokines (IL-1 cytokine family, IL-2, TNF-a, IFN-g, GM-CSF, G-CSF, 
etc.) and CC-chemokines involved in the recruitment of  mononuclear cells (MCP-1, MIP-1a, and MIP-1b) 
that play a role in pathogenesis and inflammatory pathology in the lung (29–31). We observed no statisti-
cally significant differences in proinflammatory cytokine or CC-chemokine concentrations among SARS-
CoV-2–infected macaques either untreated or treated with HCQ (Supplemental Figures 4 and 5). Notably, 
IL-6 and TNF-a concentrations were undetectable in lung tissues.
Given this observed lack of  HCQ effect in the macaque model when used either prophylactically (every 
7 days) or therapeutically (daily after infection), we sought to confirm the results in a Syrian hamster SARS-
CoV-2 disease model that had become available in the interim (12). In addition to the standard human dose 
for malaria prophylaxis/treatment (6.5 mg/kg in PBS), use of  this model enabled inclusion of  an additional 
high-dose HCQ prophylaxis/treatment regimen (50 mg/kg in PBS) to identify any dose-dependent protec-
tive activity (Figure 5A). Five groups of  hamsters (n = 6 per group) were prophylactically or therapeutically 
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treated with HCQ by intraperitoneal injection; control groups were treated by the same route with vehicle 
only. Hamsters were then intranasally infected with SARS-CoV-2 using a dose of  1 × 104 TCID50. For pro-
phylaxis, a single treatment was performed 24 hours before infection. The therapeutic treatment started 1 
hour after SARS-CoV-2 infection and was continued for 3 consecutive days. Disease manifestation in this 
model is transient and clinical signs peak between days 3 and 5 after infection with ruffled fur, increased 
respiration rate, and reduced mobility (12). Virus replication and shedding were determined by qRT-PCR in 
swab samples (oral and rectal) collected on days 2 and 4, and lung tissue was taken at necropsy on day 4 after 
infection. Regardless of  HCQ administration, all animals showed comparable high levels of  genome copy 
numbers for oral swabs (>107 genome copies/mL) and comparable lower numbers for rectal swabs (<106 
genome copies/mL), which decreased in all groups over time (Figure 5, B and C). Like viral RNA loads in 
swabs, there was no significant difference in disease manifestation over the time of  the study, which can be 
viewed by the comparable or even greater loss in weight of  the treatment groups compared with the diluent 
control group (Figure 5D). Gross lung pathology was similar among the groups consisting of  focally extensive 
areas of  consolidation that failed to collapse upon removal (Supplemental Figure 6). Viral lung loads on day 
4 were high (1012 genome copies/g and >105 TCID50/g) but indistinguishable between all groups (Figure 5, 
E and F). Lung-to-body weight ratios as a measure of  pulmonary edema were similar in all animals, with no 
significant differences between groups (Figure 5G). The presence and amount of  HCQ was measured in the 
lung tissue on day 4 after infection. Treated animals, regardless of  the dosing regimen, all displayed detectable 
amounts of  HCQ in the lung tissue. For animals for which adequate tissue mass was available for accurate 
measurement, HCQ levels were 2.5 ± 1.9 nmol/g and 3.5 ± 0.8 nmol/g for prophylactic low dose and high 
dose, respectively, and 34.3 ± 26.8 nmol/g and 107.6 ± 27.9 nmol/g for therapeutic low dose and high dose, 
respectively (Supplemental Table 2). Higher secondary HCQ metabolite levels relative to HCQ levels were 
observed in the hamster model compared with the macaque model, suggesting a more rapid drug metabolism. 
Figure 2. Rhesus macaque model — viral loads in lower and upper respiratory tract. Macaques were infected with SARS-CoV-2 as described in the legend 
of Figure 1. Swab samples (nasal and oropharyngeal) and BAL were collected at all or indicated examination time points. Viral loads were determined by 
qRT-PCR using the subgenomic E assay as genome copies. (A and B) Nasal swabs. (C and D) Oropharyngeal swabs. (E and F) BAL. No statistical signifi-
cance was found among the groups presented in A–F. Red squares indicate vehicle-treated animals and blue circles indicate HCQ-treated animals. SARS-
CoV-2, severe acute respiratory syndrome coronavirus 2; BAL, bronchoalveolar lavage; qRT-PCR, quantitative reverse transcriptase PCR; HCQ, hydroxychlo-
roquine; PS, prophylaxis; TS, treatment.
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Despite these differences in metabolism, HCQ was present in hamster lungs at levels similar to the macaque 
model, supporting a similar recruitment from the bloodstream to the tissue. To estimate concentration within 
the tissue, a homogenous distribution was assumed with a tissue water content of  80% by weight (28). Under 
these constraints, the minimum calculated value equates to 1.8 μM HCQ, which falls within but at the lower 
end of  the therapeutic window, whereas the highest calculated concentration equates to 177 μM, which is 
10-fold higher than the highest reported IC50 (7). In summary, HCQ administered either prophylactically or as 
a treatment at standard or high doses reached concentrations in the infected lung tissue that were within the 
target range, but it did not have any significant impact on SARS-CoV-2 replication and shedding or disease 
manifestation and progression in the Syrian hamster model.
Discussion
In this study, we used 2 established COVID-19–like animal models that are consistent with mild-to-mod-
erate disease in humans (12, 13) and applied the standard weight-based oral administration of  HCQ pro-
phylaxis and treatment of  malaria in humans (17, 18). The use of  the Syrian hamster model also enabled 
inclusion of  a high-dose HCQ regimen (7.5 times the standard dose regimen) both prophylactically and as 
a treatment to assess any dosage effect. This dose of  50 mg/kg had been previously shown to be associated 
with no adverse effects in Syrian hamsters (32); the lack of  this assurance for rhesus macaques prevented 
use of  such a high-dosing regimen because of  veterinary concerns of  toxicity. For prophylaxis, we used a 
weekly dosing regimen that has been standardly adopted for prevention of  malaria; it is also the dosing 
Figure 3. Rhesus macaque model — gross and histopathology. Macaques were infected with SARS-CoV-2 as described 
in the legend of Figure 1. Animals were euthanized on day 7 after infection for gross pathology and histopathology. 
(A and B) Gross pathology with consolidated lower left lung lobe and area of postmortem BAL in the lower right lung 
lobe (asterisk). (C) H&E (original magnification, ×100) and IHC (original magnification, ×200). H&E staining in both the 
hydroxychloroquine and vehicle groups revealed multifocal, minimal-to-moderate, interstitial pneumonia frequently 
centered on terminal bronchioles. Alveolar edema and fibrin with formation of hyaline membranes were seen only in 
lungs with moderate changes. Multifocal perivascular infiltrates of small numbers of lymphocytes that form peri-
vascular cuffs. Corresponding IHC showing immunopositivity in type I and II pneumocytes. Black measurement bars 
represent 50 μm for H&E and 20 μm for IHC figures. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; 
BAL, bronchoalveolar lavage; PS, prophylaxis; TS, treatment.
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schedule adopted by developing countries such as India with an aim toward prevention of  COVID-19 (16). 
For treatment, we administered HCQ starting shortly after infection and continued daily until study end. 
HCQ pharmacokinetic studies in humans and animal models have demonstrated a rapid blood bioavail-
ability after oral administration, with peak levels being reached in 2 to 4 hours followed by rapid absorption 
in various tissues including the lung (21, 26). To assess whether changes in drug metabolism after infection 
played a role in bioavailability, plasma samples for pharmacokinetic analysis were collected when the drug 
levels were at their lowest, just before the administration of  the next treatment. These levels were consistent 
with those expected from previous animal and human studies at 12 to 24 hours after administration (21). 
Based on these previous models, the maximum blood concentration is likely 2 to 3 orders of  magnitude 
higher than these minimum values. At the site of  infection within the lung, the measurements taken during 
both studies indicate accumulation of  drug at or above estimated therapeutic levels based on EC50 values 
against SARS-CoV-2 from in vitro studies (6–8, 14).
The use of  HCQ and chloroquine as treatment options for patients with COVID-19 may have been par-
tially rooted in early observations for their effect in impairing SARS-CoV-2 replication in vitro (6–8). These 
in vitro studies, which we confirmed herein, identified HCQ (and other 4-aminoquinolines) as potent inhib-
itors of  coronaviruses, including SARS-CoV-2, with low EC50 values within the range of  antivirals such as 
remdesivir (6), a drug that is now approved by the FDA as an Emergency Use Authorization for COVID-19 
Figure 4. Rhesus macaque model — viral loads in respiratory tissues. Macaques were infected with SARS-CoV-2 as described in the legend of Figure 
1. Animals were euthanized on day 7 after infection for viral tissue load determination performed by qRT-PCR (subgenomic copies) and virus isolation 
(infectious virus). (A) Viral loads in lower and upper respiratory tissues and mediastinal lymph nodes for the prophylaxis study arm (PS). Virus isolation is 
indicated in numbers on top (n/5). (B) Viral lung loads (PS). All lung lobe genome copy data were combined. (C) Viral loads in lower and upper respiratory 
tissues and mediastinal lymph nodes for the treatment study arm (TS). Virus isolation frequency (number of animals per group) is indicated at top (n/5). 
(D) Viral lung loads (TS). All lung lobe genome copy data were combined. No statistical significance was found among groups presented in parts A–D. A lin-
ear model was used to analyze viral RNA levels in tissues and lung lobes. No significant difference was found between groups in either study. Red squares 
indicate vehicle-treated animals and blue circles indicate HCQ-treated animals. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; qRT-PCR, 
quantitative reverse transcriptase PCR; HCQ, hydroxychloroquine; PS, prophylaxis; TS, treatment.
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Figure 5. Syrian hamster model — viral shedding, viral load and pathology. Hamsters were infected with SARS-CoV-2 by the intranasal route (I). (A) HCQ 
(T) was administered either prophylactically 1 time at 24 hours before infection (6.5 mg/kg and 50 mg/kg) or as a treatment starting 1 hour after infection 
and continuing every 24 hours for 3 consecutive days (6.5 mg/kg and 50 mg/kg). Hamsters were scored for clinical signs daily and swabs (oral and rectal) 
were collected 48 and 96 hours after infection (S). Animals were euthanized on day 4 and lungs were harvested for pathology and virology. Swab and lung 
loads were determined by qRT-PCR. (B and C) Viral shedding. Oral and rectal swabs collected on days 2 and 4 were analyzed for viral genome copies by 
qRT-PCR. (D) Percent weight change. Hamsters were weighed daily as a parameter to measure disease progression. Daily weights were compared with 
starting weights to generate a percent change. (E) Viral load in lung tissue. Lung viral loads (E assay, genome copies) were determined as a correlate for 
lower respiratory tract infection. (F) Infectious lung titers. Lung samples were titrated for infectious virus. No statistical significance was found between 
the groups presented in parts B–F. (G) Lung-to-body weight ratio. Lung-to-body weight ratio was determined as an indicator for pneumonia with lung 
edema. Statistically significant differences were found only when compared with lung-to-body weight ratios of naive hamsters. SARS-CoV-2, severe acute 
respiratory syndrome coronavirus 2; HCQ, hydroxychloroquine; qRT-PCR, quantitative reverse transcriptase PCR.
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cases. The mechanism of  action of  4-aminoquinolones against SARS-CoV-2 in vitro is not well defined, but 
increasing endosomal pH, inhibition of  autophagosome-lysosome fusion, impairment of  enzymes import-
ant for virus replication, and effects on protein glycosylation have been proposed, which may result in inter-
ference with SARS-CoV-2 entry/fusion, replication, and spread (33, 34). However, despite the promising in 
vitro effect observed by us and others, we did not observe any significant prophylactic or therapeutic benefit 
of  HCQ after in vivo infection in 2 animal disease models. Recent studies showing cell type–specific differ-
ences in SARS-CoV-2 replication offer one possible explanation for the disconnect between in vitro and in 
vivo studies. Specifically, these studies have shown that the SARS-CoV-2 uses a distinct entry pathway in 
the Vero cells compared with the pathway used in lung epithelium in vitro and presumably in vivo. Notably, 
only the entry pathway in Vero cells, but not lung epithelial cells, is susceptible to in vitro inhibition by 
endosomal pathway inhibitors such as HCQ (35, 36).
The use of  HCQ to treat COVID-19 has been controversial since the results of  the first clinical trials 
(9, 10). Nevertheless, HCQ has been promoted as a COVID-19 treatment option and became part of  mul-
tiple, recent, large-scale clinical trials, including 1 of  4 initial treatment options in the multinational WHO 
“Solidarity” clinical trial for COVID-19 (37). However, HCQ treatment does not come without risks; the 
4-aminoquinolones are associated with multiple adverse effects such cutaneous adverse reactions, hepatic 
failure, and ventricular arrhythmia; overdose is also difficult to treat (17). The FDA recently updated its 
guidance by warning against use of  HCQ outside of  the hospital setting because of  these potential serious 
adverse effects (38). HCQ treatment was recently removed from the WHO Solidarity COVID-19 clinical 
study based on evidence from a report, among others, from the UK-based RECOVERY trial, wherein HCQ 
showed no effect on the mortality rate of  patients with COVID-19 (37, 39, 40). Similarly, a postexposure 
prophylaxis trial showed no effect of  HCQ on the incidence of  infection from high-risk and moderate-risk 
exposure to SARS-CoV-2 (15). Nevertheless, multiple preexposure prophylaxis trials remain ongoing (4). 
In addition, a preclinical study in cynomolgus macaques has been recently published (41). This study used 
daily administration of  high-dose HCQ and therefore does not relate to the dosing levels used in our study 
or ongoing human prophylactic studies, especially in developing nations. Interestingly, in this cynomolgus 
macaque study, HCQ treatment did not show any significant effect on SARS-CoV-2 replication and HCQ 
prophylaxis did not confer protection against SARS-CoV-2 infection, which further supports our preclinical 
data. Clearly, the effectiveness of  HCQ to prevent or reduce infection, thereby impacting the clinical course 
of  COVID-19, remains highly contentious at this time.
In conclusion, when used at the standard dosing regimen for malaria prophylaxis and treatment, HCQ 
had no beneficial effect on SARS-CoV-2 replication and shedding or on disease progression and outcome 
in the 2 animal models tested. Potential benefits of  HCQ on immunomodulation was difficult to measure in 
a clinically relevant fashion in our studies, as neither the macaque model nor the hamster model mimicked 
the presumed immune-mediated pathogenic responses seen in severe, late-stage COVID-19 cases. However, 
no differences were observed in any of  the multiple immunomodulatory molecules tested in HCQ-treated 
versus nontreated macaques when measured at necropsy (day 7). There is always the consideration as to 
what extent animal data can be extended to the situation in humans, but in general the nonhuman primate 
models are considered good indicators and the ultimate preclinical models before moving drugs into clin-
ical trials. The preclinical data presented here may help guide future decisions regarding HCQ and likely 
other 4-aminoquinolines in terms of  the potential utility of  these drugs for prophylaxis or treatment of  
SARS-CoV-2 infections.
Methods
Virus and cells. SARS-CoV-2 isolate nCoV-WA1-2020 (MN985325.1) was provided by CDC and propagated 
once at Rocky Mountain Laboratories (RML) in Vero E6 cells in DMEM (MilliporeSigma) supplemented 
with 2% FBS (Gibco), 1 mM L-glutamine (Gibco), 50 U/mL penicillin, and 50 μg/mL streptomycin (Gibco). 
The used virus stock was Vero passage 4, which is free of  contaminations and confirmed to be identical to the 
initial deposited GenBank sequence (MN985325.1). Vero E6 cells were maintained in DMEM supplemented 
with 10% fetal calf  serum, 1 mM L-glutamine, 50 U/mL penicillin, and 50 μg/mL streptomycin.
Rhesus macaque study design. The study consisted of  2 arms, prophylaxis and treatment (Figure 1, A and 
B). Animals were anesthetized for all procedures. For the prophylaxis arm, 10 healthy rhesus macaques 
between 3 and 4 years of  age (all male; 4.9–5.6 kg in weight) were randomly divided into vehicle control 
(n = 5) and HCQ prophylaxis (n = 5) groups. Animals were treated with either vehicle (PBS) or HCQ 
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(6.5 mg/kg in PBS) 3 times 1 week apart (days –9, day –2, and day 5) by oral gavage. In the second part, 
10 healthy rhesus macaques between 3 and 4 years of  age (all male; 5.7–7.3 kg in weight) were randomly 
divided into vehicle control (n = 5) and HCQ treatment (n = 5) group. Animals were treated with either 
vehicle (PBS) or HCQ (6.5 mg/kg in PBS) starting 12 hours after infection followed by treatment 18, 36, 
60, 84, 108, 132, and 156 hours after infection by oral gavage. All animals were infected on day 0 with a 
total dose of  2.8 × 106 TCID50 of  SARS-CoV-2 by a combination of  4 routes (intratracheal, oral, intranasal 
and ocular). Animals were monitored at least twice daily using an established scoring sheet by the same 
person, who was blinded to the group assignments, throughout the study (19). Physical examinations were 
performed on days –9, –2, 0, 1, 3, 5, and 7 and included a clinical evaluation, radiographs, venous blood 
draw, and swabs (oral, nasal, and rectal). BAL was performed on day 3, 5, and 7 after infection. The study 
endpoint was day 7. After euthanasia, necropsies were performed, and gross lung lesions were scored by a 
board-certified veterinary pathologist blinded to the group assignment.
Syrian hamster study design. The hamster study also was designed with 2 arms, prophylaxis and thera-
peutic. Hamsters were divided into groups for either prophylaxis treatments or therapeutic treatments (n = 
6 per group). Two groups were treated 1 time with either a 6.5 mg/kg or 50 mg/kg 24 hours before infec-
tion for the prophylaxis arm. There were 2 therapeutic groups: 1 group received 6.5 mg/kg and the second 
received 50 mg/kg. Treatments began 1-hour after infection and were performed every 24 hours on days 1, 
2, and 3 after infection. A final group consisted of  vehicle control animals that received the same volume of  
PBS as the prophylactic and therapeutic groups. All groups were infected intranasally with 1 × 104 TCID50 
of  SARS-CoV-2 (50 μL/nare). Animals were weighed daily and the D0 weight was used as the baseline to 
calculate percent weight change over the course of  the study. Animals were euthanized and samples were 
collected on day 4 after infection. All procedures were performed on anesthetized animals. Swabs (oral, 
rectal) were collected on days 2 and 4, and lung tissues were collected at necropsy on day 4 after infection 
for pathology and virology.
Liquid chromatography and mass spectrometry (LC–MS). LC–MS grade water, methanol, acetonitrile, and 
formic acid were purchased through Fisher Scientific. All synthetic standards for molecular analysis were 
purchased from Santa Cruz Biotechnology. Levels of  HCQ and secondary metabolites were determined using 
methodology established previously with modifications (23). Plasma and cleared lung homogenates were 
γ-irradiated (2 × 104 Gy) before removal from biocontainment according to IBC-approved protocol. Plasma 
samples were prepared for small molecule analysis by diluting a 25 μL aliquot with 100 μL of 0.1% formic 
acid and 1 mL of acetonitrile on ice. Clarified lung homogenate samples were prepared by adding 1 mL of  
acetonitrile to a 250 μL aliquot of  lung homogenate. Samples were vortexed and incubated at –20°C for 
2 hours. Samples were centrifuged at 16,000g and 4oC for 20 minutes. The clarified supernatants (1 mL) 
were recovered and taken to dryness in a Savant DNA120 SpeedVac concentrator (Thermo Fisher Scientif-
ic). Samples were resuspended in 100 μL of 50% methanol and 50% water (v/v) and centrifuged as before. 
The supernatant was taken to a sample vial for LC–MS analysis. Samples were separated by reverse-phase 
chromatography on a Sciex ExionLC AC system. Samples were injected onto a Waters Atlantis T3 column 
(100Å, 3 μm, 3 mm × 100 mm) and eluted using a binary gradient from 25% methanol, 0.1% formic acid 
to 100% methanol formic acid over 4 minutes. Analytes were measured using a Sciex 5500 QTRAP mass 
spectrometer in positive mode. Multiple reaction monitoring was performed using previously established sig-
nal pairs for each analyte and signal fidelity was confirmed by collecting triggered product ion spectra and 
comparing back to spectra of  synthetically pure standards. All analytes were quantified against an 8-point 
calibration curve of  the respective synthetic standard prepared in the target matrix and processed in the same 
manner as experimental samples. Limits of  quantification in plasma for all metabolites was 0.5 ng/mL. Limit 
of  quantification in lung homogenate for all metabolites was 6 ng/mL apparent and sample data were filtered 
before weight normalization.
Hematology and serum chemistry. Hematology was completed on a Procyte DX (IDEXX Laboratories) and 
the following parameters were evaluated: RBCs, hemoglobin, hematocrit, mean corpuscular volume, mean 
corpuscular hemoglobin (MCH), MCH concentration, red cell distribution weight, platelets, mean platelet 
volume, WBCs, neutrophil count (abs and %), lymphocyte count (abs and %), monocyte count (abs and 
%), eosinophil count (abs and %), and basophil count (abs and %). Serum chemistries were completed on a 
Vetscan VS2 Chemistry Analyzer (Abaxis) and the following parameters were evaluated: glucose, blood urea 
nitrogen, creatinine, calcium, albumin, total protein, alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, total bilirubin, globulin, sodium, potassium, chloride, and total carbon dioxide.
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Thoracic radiographs. Ventro-dorsal and right/left lateral radiographs were taken of  nonhuman pri-
mates on clinical exam days and scored for the presence of  pulmonary infiltrates by 2 clinical veterinarians 
according to a standard scoring system (0, normal; 1, mild interstitial pulmonary infiltrates; 2, moderate 
pulmonary infiltrates perhaps with partial cardiac border effacement and small areas of  pulmonary con-
solidation; 3, serious interstitial infiltrates, alveolar patterns, and air bronchograms). Individual lobes were 
scored. Scores from the lobes were then totaled and recorded per animal per day.
Virus load. RNA was extracted from swabs and BAL using the QIAamp Viral RNA Kit (QIAGEN) 
according to the manufacturer’s instructions. Tissues were homogenized in RLT buffer and RNA was 
extracted using the RNeasy Kit (QIAGEN) according to the manufacturer’s instructions. For detection 
of  viral RNA, 5 μl RNA was used in a 1-step real-time RT-PCR assay for total RNA using E (13) or an 
E subgenomic mRNA (42) using the Rotor-Gene Probe Kit (QIAGEN) according to instructions of  the 
manufacturer. In each run, standard dilutions of  RNA standards counted by droplet digital PCR were run 
in parallel, to calculate copy numbers in the samples.
Virus titration. Virus isolation was performed on lung tissues by homogenizing the tissue in 1 mL 
DMEM using a TissueLyser (QIAGEN) and inoculating Vero E6 cells in a 24-well plate with 250 μL 
of  cleared and a 1:10 dilution of  the homogenate. One hour after inoculation of  cells, the inoculum was 
removed and replaced with 500 μL DMEM (MilliporeSigma) supplemented with 2% FBS, 1 mM L-gluta-
mine, 50 U/mL penicillin, and 50 μg/mL streptomycin. Six days after inoculation, cytopathogenic effect 
was scored and the TCID50 was calculated.
Cytokine analysis. A small lung sample was excised from every lung lobe from each macaque and placed 
into 1mL plain DMEM (6 samples per macaque). To disrupt cell membranes, tissue samples were sonicated 
and then centrifuged to clarify the supernatant. Supernatants were then collected and stored at −80 °C until 
use. Lung homogenates were diluted at 1/4 with plain DMEM. The concentrations of  cytokines and chemo-
kines present in the lung homogenates were quantified using the MILLIPLEX MAP Non-Human Primate 
Cytokine Magnetic Bead Panel - PCYTMG-40 K- Cytokine-Chemokine Array Kit (Millipore) following the 
manufacturer’s instructions. The analytes detected by this panel are as follows: G-CSF, GM-CSF, IFN-g, 
IL-1ra, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 (p40), IL-13, IL-15, IL-17, IL-18, MCP-1, MIP-1a, 
MIP-1b, sCD40L, TGF-a, TNF-a, and VEGF. The multiplex plate was read using a Bio-Plex 200 Suspension 
Array Luminex System (Bio-Rad). Data were normalized based on the tissue weight.
Histopathology and IHC. Histopathology and IHC were performed on rhesus macaque tissues. After 
fixation for a minimum of  7 days in 10% neutral-buffered formalin and embedding in paraffin, tissue sec-
tions were stained with H&E. Tissues were placed in cassettes and processed with a Sakura VIP-6 Tis-
sue Tek on a 12-hour automated schedule, using a graded series of  ethanol, xylene, and ParaPlast Extra. 
Embedded tissues were sectioned at 5 μm and dried overnight at 42°C before staining. Specific anti-CoV 
immunoreactivity was detected using GenScript U864YFA140-4/CB2093 NP-1 at a 1:1000 dilution. The 
secondary antibody was an anti–rabbit IgG polymer from Vector Laboratories ImPress VR. Tissues were 
then processed for IHC using the Discovery Ultra automated processor (Ventana Medical Systems) with 
a ChromoMap DAB Kit (Roche Tissue Diagnostics). Stained slides were analyzed by a board-certified 
veterinary pathologist.
Statistics. Statistical analysis was performed in Prism 8 (GraphPad). Two-tailed t tests were used to 
compare experiments consisting of  2 experimental groups. One-way ANOVA was used to analyze all data 
sets with more than 2 experimental groups. A P value of  less than 0.05 was considered significant.
Study approval. Work with infectious SARS-CoV-2 was approved by the Institutional Biosafety Com-
mittee (IBC) and performed in high biocontainment at RML, National Institute of  Allergy and Infectious 
Diseases (NIAID), NIH. Sample removal from high biocontainment followed IBC-approved standard 
operating protocols. Animal work was approved by the Institutional Animal Care and Use Committee and 
performed by certified staff  in an AALAC International-accredited facility. Work followed the institution’s 
guidelines for animal use, the guidelines and basic principles in the NIH Guide for the Care and Use of  Labo-
ratory Animals (National Academies Press, 2011), the Animal Welfare Act, US Department of  Agriculture, 
and the US Public Health Service Policy on Humane Care and Use of  Laboratory Animals. Syrian ham-
sters were group-housed in HEPA-filtered cage systems enriched with nesting material and were provided 
with commercial chow and water ad libitum. Nonhuman primates were single-housed in adjacent primate 
cages, allowing social interactions, in a climate-controlled room with a fixed light/dark cycle (12-hour 
light/12-hour dark). They were provided with commercial monkey chow, treats, and fruit twice daily with 
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water ad libitum. Environmental enrichment consisted of  a variety of  human interaction, manipulanda, 
commercial toys, videos, and music. Hamsters and nonhuman primates were monitored at least twice daily.
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